Abstract 37P
Background
Chemotherapy, as one of the main therapies to treat breast cancer, may result in undesirable side effects. It may disrupt the haematological system and cause disorders as a result of chemotoxicity. This condition may lead to a declining in Quality of Life (QoL) of the patients. There were limited data reported from Indonesia about the correlation between haematological chemotoxicity and QoL. Thus, the aim to find the association between them.
Methods
This was a cohort-prospective study which includes 50 breast cancer patients who undergone first-cycle of chemotherapy. Patients who had haematological abnormalities and poor quality of life before chemotherapy were excluded. Patient’s QoL was measured by QLQ-BR23 questionnaire which includes body image (BI); sexual functioning (SF); sexual enjoyment (SE); future perspective (FP); and functional total (FT). Haematological chemotherapy toxicity was determined by the number of haemoglobins, leukocytes count and platelet count. Chemotherapy toxicity is graded from 0 (no toxicity) to 5 (death) according to the National Common Institute Common Terminology Criteria for Adverse Events. Correlation is analysed with Pearson Correlation using SPSS version 25.0.
Results
65 patients were included in this study (mean age 46.98 ± 9.05). The correlation between haematological chemotoxicity and BI; SF; SE; FP; and FT were described as follow: Hb r = -0,3; -0.251; -0.498; -0.345; and -0.61 respectively, with p = 0.08; 0.044; 0.01; 0.283; and 0.02 respectively. Leukocyte r = -0.41; -0.121; -0.128; -0.7; -0.3 respectively, with p = 0.01; 0.3; 0.3; 0.02; 0.05 respectively. Platelet r = -0.123; -0.31; -0.7; -0.9; -0.042 respectively, with p = 0.3; 0.03; 0.04; 0.1; 0.05 respectively.
Conclusions
We found that Hb and platelet level is significantly correlated with sexual functioning, sexual enjoyment, and functional total. Meanwhile, the leukocyte level is significantly correlated with body image, future perspective, and functional total.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session